Tag: ASH
ASH 2020: Preclinical Models Identify CD74 as Potential Target for the...
Presentations during the virtual 62nd American Society of Hematology (ASH) Annual Meeting for the ongoing Phase 1 dose-escalation clinical trial with STRO-001, a CD74-targeted...
ASH 2020: Potential of Belantamab Mafodotin in Combination Standard Therapies in...
Multiple myeloma is the second most common hematological malignancy in the United States and is generally considered treatable, but not curable. Multiple myeloma...
ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential...
New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients with relapsed/refractory acute myeloid leukemia...
Promising Preclinical Results Show Antibody Effectively Targets CD74 in Lymphoma and...
Two studies presented at the annual meeting of the American Society of Hematology (ASH), held December 9 - 12, 2017, showed frequent expression of...
GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma...
The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and...
The Lancet Publishes Positive Phase III Trial Data of Brentuximab Vedotin...
Data from the randomized Phase III ALCANZA clinical trial evaluating brentuximab vedotin (Adcetris®) in patients with cutaneous T-cell lymphoma (CTCL) were published in the...
Clinical Hold on Several Phase I Trials of Vadastuximab Talirine; Enrollment...
Earlier today Seattle Genetics, an innovative biotechnology company that develops and commercializes novel antibody-based therapies for the treatment of cancer, confirmed that it has...
Combination of Brentuximab Vedotin + Nivolumab Shows 90% Objective Response Rate...
The first reported data from an ongoing phase I/II clinical trial evaluating brentuximab vedotin (Adcetris®; Seattle Genetics) in combination with nivolumab (Opdivo; Bristol-Myers Squibb...
Antibody-drug Conjugate Targeting CD74 Exhibits Potent Anti-tumor Activity in Multiple Malignant...
Sutro Biopharma, a biotechnology company developing best-in-class antibody drug conjugate (ADC) and multi-specific antibody-based therapeutics for cancer therapy, including immune-oncology therapies has launched IND-enabling studies, including...
Brentuximab Vedotin Identified as Potentially Transformational in Hodgkin’s lymphoma Treament
Earlier this month, during the 57th Annual Meeting and Exposition of the American Society of Hematology (ASH), held in Orlando, Florida from December 5–8,...
